Real Research S.A. is carrying out a project titled “Development of an innovative, ready-to-use 3D culture-based model for preclinical research of new targeted therapies and immunotherapy for lung and ovarian cancer,” co-financed by the European Union funds under the European Funds for the Modern Economy Program.
The research will be conducted in three stages of the R&D module:
Stage 1) Optimization of 3DCC for selected lung and ovarian cancer cell lines using LifeGel hydrogel.
Stage 2) Comparison of the gene expression profile for the cell lines selected in Task 1 for lung and ovarian cancer, cultured in 2D, 3DCC, and propagated in an animal model. Optimization of transport conditions for the model to potential clients.
Stage 3) Validation of the 3DCC model for assessing sensitivity/resistance to targeted drug therapies and immunotherapy with seeded cells from selected lung and ovarian cancer cell lines under optimal growth conditions on LifeGel.
The target groups for the market introduction of the developed products will include biotechnology and pharmaceutical companies, contract research laboratories, and scientific institutes.
The aim of the project is to develop an innovative, ready-to-use 3D-based model for preclinical research on new targeted therapies and immunotherapy for lung and ovarian cancer. The project will focus on developing 3D cell culture (3DCC) models for cancer cell lines, which have the potential for high-throughput screening. As a result of the project, reliable preclinical in vitro models will be developed, with a real chance of obtaining FDA approval, and will have practical applications for the treatment of lung and ovarian cancers.
The outcome of the project will be world-first truly ready-to-use, widely validated in vitro models for assessing sensitivity/resistance to targeted therapies and immunotherapy with lung and ovarian cancer cell lines seeded on LifeGel hydrogel. The final result of the project will be implemented into the applicant’s business operations by including it in the beneficiary’s core product offer.
Project value: 6 120 045,47 PLN
Funding value: 4 221 103,00 PLN
#EUFunds #EuropeanFunds